MAPT and Alzheimer disease: In addition to characterizing the earliest progressive changes associated with the preclinical stages of AD, including but not limited to biological measurements of amyloid-β pathology, tau pathology and neurodegeneration, there is an emerging interest in the identification of even earlier, neurodevelopmental changes, some of which may provide a foothold for AD pathology at older ages.